FDA rais­es an­timi­cro­bial re­sis­tance con­cerns ahead of ad­comm for Iterum's UTI treat­ment

The FDA has raised con­cerns about po­ten­tial “in­ap­pro­pri­ate use” of Iterum’s oral can­di­date for un­com­pli­cat­ed uri­nary tract in­fec­tions (uUTIs) ahead of a Mon­day ad­vi­so­ry com­mit­tee …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER